QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
NCT ID: NCT00974896
Last Updated: 2016-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
46 participants
INTERVENTIONAL
2006-12-31
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AMG 479 + Sorafenib cohorts
The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.
AMG 479
AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
AMG 479 + Erlotinib cohorts
The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.
AMG 479
AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AMG 479
AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women ≥ 18 years old with a pathologically or cytologically documented, advanced solid tumor that is refractory to at least one line of therapy or for whom no standard therapy is available and for which no curative therapy is available, or the subject refuses standard non-curative therapy
* Measurable disease or evaluable disease per World Health Organization (WHO) guidelines
* Eastern Cooperative Oncology Group performance status ≤ 2
* Life expectancy of 3 months as documented by the investigator
* Adequate hematologic, renal and hepatic function
Exclusion Criteria
* Subjects with primary or metastatic central nervous system (CNS) tumors are not allowed to enroll in the sorafenib cohorts. These subjects are allowed to enroll in the remaining cohorts, only if their CNS tumors have been controlled by prior surgery or radiation, and they have been neurologically stable
* History of lymphoma, leukemia, or high-dose chemotherapy with hematopoietic stem cell rescue
* Uncontrolled hypertension \[diastolic \>100 mmHg or systolic \>150 mmHg\]; Subjects enrolling in the sorafenib groups must not have diastolic \> 85 mmHg nor systolic \> 145 mmHg
* Clinically significant ECG changes which obscure the ability to assess the PR, QT, QRS intervals
* Presence of ascites or pleural effusion requiring chronic medical intervention
* Diagnosis of arterial or venous thrombosis within 6 months before enrollment; history of bleeding diathesis
* History of clinically significant hypoglycemia or hyperglycemia in the opinion of the investigator
* Myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (New York Heart Association \>class II), unstable angina, or unstable cardiac arrhythmia requiring medication
* Active peptic ulcer disease
* History of chronic hepatitis
* Subject known to have tested positive for HIV
* Known sensitivity to mammalian derived products
* Hematological function, as follows:
* Absolute neutrophil count (ANC) ≤ 1.5 x 109/L for B, P, S and E cohorts
* Absolute neutrophil count (ANC) ≤ 3 x 109/L for G cohorts
* Platelet count ≤ 100 x 109/L
* Hemoglobin ≤ 9 g/dL
* Renal function, as follows:
* Calculated creatinine clearance \< 50 ml/min using the modified Cockroft-Gault equation
* Urinary protein quantitative value of \> 30 mg or \>1+ on dipstick, unless quantitative protein is \< 500 mg in a 24 hour urine sample
* Hepatic function, as follows:
* Aspartate aminotransferase (AST) \> 2.5 x upper limit of normal (ULN) (if liver metastases are present, ≥ 5 x ULN)
* Alanine aminotransferase (ALT) \> 2.5 x ULN (if liver metastases are present, ≥ 5 x ULN)
* Alkaline phosphatase \> 2.0 x ULN (if bone or liver metastases are present, ≥ 5 x ULN)
* Bilirubin \> 2.0 x ULN
* Prothrombin time (PT) or partial thromboplastin time (PTT) \> 1.5 x ULN
* Treatment with anti-cancer therapy (6 weeks for nitrosoureas and mitomycin C chemotherapies), antibody therapy, retinoid therapy, or hormonal therapy within 4 weeks before study day 1. Prior and concurrent use of hormone replacement therapy or the use of gonadotropin-releasing hormone (GnRH) modulators for prostate cancer are permitted
* Therapeutic or palliative radiation therapy within 4 weeks before enrollment (subjects must have resolution of any significant adverse effects from radiation therapy received prior to 2 weeks before enrollment)
* Concurrent or prior (within 1 week of study Day 1) anticoagulation therapy, except low-dose warfarin (≤ 2 mg/day) for prophylaxis against central venous catheter thrombosis
* Prior participation in clinical drug trials within 4 weeks before enrollment
* For subjects receiving erlotinib, the use of ketoconazole, clarithromycin, voriconazole, troleandomycin, telithromycin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and St. John's Wort is prohibited
* For subjects receiving sorafenib, use of St. John's Wort, rifampin, phenytoin, carbamazepine, dexamethasone, and phenobarbital (CYP3A inducers) is prohibited
* Type 1 or 2 diabetics are excluded
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NantCell, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
QUILT-2.016
Identifier Type: OTHER
Identifier Source: secondary_id
20060134
Identifier Type: -
Identifier Source: org_study_id